Center for American Progress

Trump raved about his COVID treatment, but hardly anyone can get it. We need a better plan.
In the News

Trump raved about his COVID treatment, but hardly anyone can get it. We need a better plan.

Topher Spiro writes about why the monoclonal antibody treatment will not be widely available to those with COVID-19.

To find the latest CAP resources on the coronavirus, visit our coronavirus resource page.

President Donald Trump promised to provide the experimental drug he took — a cocktail of monoclonal antibodies developed by Regeneron — for free to anyone who needs it. But as a result of his administration’s failure to harness the tools of government and the private sector, extreme rationing of the treatment will occur.

Monoclonal antibodies are genetically engineered antibodies that could both treat and prevent COVID-19 infection. Regeneron reported promising preliminary results and applied for an emergency use authorization from the Food and Drug Administration. Monoclonal antibodies could be effective for populations for whom a vaccine is not authorized or effective. And because no vaccine will be 100% effective, a therapeutic is still very much needed.

The above excerpt was originally published in USA Today. Click here to view the full article.

The positions of American Progress, and our policy experts, are independent, and the findings and conclusions presented are those of American Progress alone. A full list of supporters is available here. American Progress would like to acknowledge the many generous supporters who make our work possible.

Authors

Topher Spiro

Vice President, Health Policy; Senior Fellow

You Might Also Like